MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. More Details
Excellent balance sheet and fair value.
Share Price & News
How has MediciNova's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MNOV is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: MNOV's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: MNOV underperformed the US Biotechs industry which returned 19.1% over the past year.
Return vs Market: MNOV underperformed the US Market which returned 37.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is MediciNova's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Is MediciNova undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MNOV ($3.67) is trading below our estimate of fair value ($113.66)
Significantly Below Fair Value: MNOV is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MNOV is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: MNOV is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MNOV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MNOV is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (2.8x).
How is MediciNova forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MNOV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MNOV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MNOV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MNOV's revenue (63.4% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: MNOV's revenue (63.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MNOV's Return on Equity is forecast to be low in 3 years time (0.2%).
How has MediciNova performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MNOV is currently unprofitable.
Growing Profit Margin: MNOV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MNOV is unprofitable, and losses have increased over the past 5 years at a rate of 3.7% per year.
Accelerating Growth: Unable to compare MNOV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MNOV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: MNOV has a negative Return on Equity (-12.26%), as it is currently unprofitable.
How is MediciNova's financial position?
Financial Position Analysis
Short Term Liabilities: MNOV's short term assets ($81.5M) exceed its short term liabilities ($1.8M).
Long Term Liabilities: MNOV's short term assets ($81.5M) exceed its long term liabilities ($1.9M).
Debt to Equity History and Analysis
Debt Level: MNOV is debt free.
Reducing Debt: MNOV had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MNOV has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MNOV has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is MediciNova current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MNOV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MNOV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MNOV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MNOV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MNOV's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Yuichi Iwaki (71 yo)
Dr. Yuichi Iwaki, M.D., Ph.D. served as Acting Principal Financial Officer at MediciNova, Inc. from April 22, 2020 until June 2020. Dr. Iwaki is a Co-Founder of MediciNova Inc. and has been its Chief Execu...
CEO Compensation Analysis
Compensation vs Market: Yuichi's total compensation ($USD2.97M) is above average for companies of similar size in the US market ($USD1.11M).
Compensation vs Earnings: Yuichi's compensation has been consistent with company performance over the past year.
Experienced Management: MNOV's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Experienced Board: MNOV's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.2%.
MediciNova, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: MediciNova, Inc.
- Ticker: MNOV
- Exchange: NasdaqGM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$178.981m
- Shares outstanding: 48.77m
- Website: https://medicinova.com
Number of Employees
- MediciNova, Inc.
- 4275 Executive Square
- Suite 300
- La Jolla
- United States
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company i...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/28 02:50|
|End of Day Share Price||2021/07/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.